Nanjing KAEDI Biotechnology

Nanjing Kaedi Biotechnology is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, dedicated to the innovation of chimeric antigen receptor T-cell (CAR-T) therapies. The company primarily focuses on the treatment of solid tumors, a significant challenge in the field of immunotherapy, utilizing its proprietary KD-Smart and KD-T technology platforms. These platforms are designed to enhance the expansion, persistence, and tumor-killing efficacy of T-cells within the immunosuppressive tumor microenvironment. Kaedi's robust pipeline includes candidates targeting Mesothelin, Glypican-3, and Claudin 18.2 for various gastrointestinal and hepatic cancers. By integrating advanced genetic engineering with clinical research, the company aims to deliver transformative cell-based treatments to patients worldwide.